The longtime head of Sanofi's Genzyme unit, David Meeker, will step down and be succeeded by Bill Sibold as the Cambridge, Mass.-based group embarks on an important transition with the launch of Dupixent (dupilumab). Sanofi announced April 5 that Sibold will take the reigns as executive vice president of Sanofi Genzyme after working to prepare for the launch of Dupixent as the head of Sanofi Genzyme's Global Multiple Sclerosis, Oncology and Immunology organization.
Longtime Genzyme Holdout Meeker Passes Reigns To Sibold
Bill Sibold will take over the leadership of Sanofi's Cambridge-based Genzyme group as the unit begins the important launch of Dupixent. Meeker ends his career at Genzyme after 23 years.